ClinicalTrials.gg
CompletedNCT01705236PASSOSUpdated Mar 2, 2020Results posted

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®

A Phase 4 interventional study of Fingolimod in Relapsing Remitting Multiple Sclerosis RRMS, sponsored by Novartis Pharmaceuticals. Completed at 10 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-03-02.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
87
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.

Enrollment
25th of 34
87 · median 167
Started
2012
with 3 others
Phase 4
17 of 34
none open now
Registered
23rd of 34
by date
Lead sponsor
20 of 34
Novartis Pharmaceuticals

Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 25th largest by enrollment, is one of 4 that started in 2012, is one of 17 in phase 4, and was the 23rd registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing fingolimod in Multiple Sclerosis, or all of them as a file.
02

Study summary

This was a 3-year, prospective, multi-center, open-label study to describe the long term changes of optical coherence tomography (OCT) parameters in RRMS patients under treatment with Fingolimod. It was designed to longitudinally study the degeneration of retinal axons by measuring change in RNFL thickness by latest OCT-technology.

03

Conditions studied

  • Relapsing Remitting Multiple Sclerosis RRMS

Browse trials for

Keywords

  • Multiple sclerosis (MS)
  • MS
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients eligible for inclusion in this study have to fulfill all of the following criteria:

  1. Written must be obtained before any assessment is performed.
  2. Male or female subjects aged 18-65 years.
  3. Subjects with relapsing remitting MS defined by 2010 revised McDonald criteria (see Appendix 4).
  4. Patients with Expanded Disability Status Scale (EDSS) score of 0-6.0 inclusive (see Appendix 6).
  5. Patients stable on immunomodulatory treatment with fingolimod for at least 1 month and at most 4 months prior to screening according to local label
  6. Neurologically stable with no evidence of relapse within 30 days prior to inclusion date
  7. Sufficient ability to read, write, communicate and understand

Exclusion criteria

Exclusion Criteria

Patients fulfilling any of the following criteria are not eligible for inclusion in this study:

  1. Patients who have been treated with:

    • systemic or immunoglobulins within 1 month prior to screening;
    • medications such as azathioprine, cyclophosphamide, or methotrexate within 3 months prior to screening;
    • monoclonal antibodies (including natalizumab) within 3 months prior to screening;
    • mitoxantrone within 6 months prior to screening
    • cladribine at any time.
  2. Patients with any medically unstable condition, as assessed by the primary treating physician at each site.
  3. Patients with any of the following cardiovascular conditions :

    • history of myocardial infarction or with current unstable ischemic heart disease;
    • Heart failure ( III-IV) or any severe cardiac disease as determined by the Investigator (see Appendix 5);
    • history or presence of a second-degree AV block, Type II or a third-degree AV block
    • patients receiving Class Ia (ajmaline, disopyramide, procainamide, quinidine) or III antiarrhythmic drugs (e.g., amiodarone, bretylium, sotalol, ibulitide, azimilide, dofelitide);
    • proven history of sick sinus syndrome;
    • uncontrolled hypertension
  4. Patients with severe respiratory disease, pulmonary fibrosis, or (Class III-IV).
  5. Patients with history of specific MRI findings (tumor, subdural haematoma, post-contusional changes, territorial stroke, neurodegenerative disorders, aneurysm/arteriovenous malformation, evidence of past macroscopic haemorrhage, or other relevant MRI findings that would interfere with evaluation)
  6. Any severe disability or clinical impairment that can prevent the patient to meet all study requirements at the investigator's discretion
  7. History of of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or , with the exception of localized basal cell carcinoma of the skin
  8. Patients who have received an drug (excluding fingolimod) or therapy within 90 days or 5 half-lives of screening, whichever is longer.
  9. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG test (serum)
  10. Patients with any ophthalmologic reason for RNFL pathology other than MS, such as: optic neuropathy, active advanced glaucoma, injury of the optic nerve based on the ophthalmologist's clinical judgment
  11. history or presence of severe myopia

    1. in patients who have not had refractive surgery, a refractive error of greater than 6.00 diopters
    2. pathologic fundus changes of high myopia, such as retinal pigmentary atrophy, besides peripapillary atrophy (atrophy involving the macula) or a staphyloma
    3. in patients that have had previous refractive surgery, an axial eye length of greater than 26 mm
  12. Acute optic neuritis within the past 6 months before screening
  13. Evidence of advanced, non-proliferative or proliferative diabetic retinopathy
  14. Presence of retinal conditions associated with edema, subretinal fluid, cysts, etc.
  15. Concomitant use of drugs that may directly affect retinal structure and function (e.g.

chronic systemic corticosteroids [>30 consecutive days; doses higher than Cushing threshold e.g. prednisone 7.5mg/d], intraocular anti-angiogenic drugs [ranibizumab, bevacizumab], intraocular steroids etc.)

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Fingolimod - Longitudinal Assessment

    No study drug was provided. Fingolimod was to be prescribed according to local label. The decision to prescribe fingolimod had to be made independent of this study.

    Drug: Fingolimod

Interventions

  • All subjects received an oral dose of 0.5 mg fingolimod (FTY720) per capsule (hard gelatin capsules) once daily according to local label for the treatment of their MS.

    Also known as: FTY720

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Month 36 in Average Retinal Nerve Fiber Layer Thickness (RNFLT)

    The primary endpoint was the change, i.e. the absolute difference, in average RNFL thickness from baseline to month 36 (or last values in case of missing data) in the Full Analysis Set (FAS). Average RNFL thickness was the average of valid measurements of the right and left eye and assessed by optical coherence tomography (OCT).

    Time frame: Baseline, month 36

Secondary outcomes

  1. Change From Baseline to Month 12 and 24 in Average Retinal Nerve Fiber Layer Thickness (RNFLT)

    Change from baseline in average RNFL thickness to months 12 and 24 (or last values in case of missing data) in the Full Analysis Set (FAS). Average RNFL thickness was the average of valid measurements of the right and left eye and assessed by optical coherence tomography (OCT).

    Time frame: Baseline, month 12, month 24

  2. Change From Baseline to Month 12, 24 and 36 in Average Quadrant Retinal Nerve Fiber Layer Thickness (RNFLT)

    Change from baseline in average quadrant RNFL thickness to months 12, 24 and 36 (or last values in case of missing data) in the Full Analysis Set (FAS). Average quadrant RNFL thickness was the average of valid measurements of the right and left eye and assessed by optical coherence tomography (OCT). Quadrant RNFL thickness were: Nasal-inferior; nasal-superior; temporal-inferior; temporal-superior.

    Time frame: Baseline, month 12, month 24, month 36

  3. Change From Baseline to Month 12, 24 and 36 in Total Macular Volume (TMV)

    Change from baseline in TMV to months 12, 24 and 36 (or last values in case of missing data) in the Full Analysis Set (FAS).

    Time frame: 12, 24 and 36 months

  4. Change From Baseline to Month 12, 24 and 36 in Ganglion Cell Inner Plexiform (GCIP)

    Change from baseline in GCIP to months 12, 24 and 36 (or last values in case of missing data) in the Full Analysis Set (FAS). The change in Ganglion cell layer thickness (GCLT) had been defined as secondary endpoint in the protocol, but OCT measured the GCIP instead. This was done because both layers were not clearly separable by OCT. GCIP was calculated as mean of the inner sectors (nasal, superior, temporal, and inferior) and declared as usual parameter instead. This change was introduced prior to data base lock, but the derivation of GCIP was corrected after data base lock.

    Time frame: Baseline, month 12, month 24, month 36

  5. Number of Participants With Adverse Events

    Number of participants with adverse events and specifically macular edema.

    Time frame: 36 months

07

Results

Posted Mar 2, 2020

Participant flow

Subjects were screened at 10 study centers in Germany (9 centers) and Switzerland (1 center).

Participant flow — Overall Study
MilestoneFingolimod - Longitudinal Assessment
Started87
Completed60
Not completed27
Withdrew: Lost to follow-up1
Withdrew: Administrative problems2
Withdrew: Unsatisfactory therapeutic effect3
Withdrew: Protocol violation3
Withdrew: Abnormal test procedure result(s)4
Withdrew: Abnormal laboratory value(s)4
Withdrew: Withdrawal by subject5
Withdrew: Adverse event5

Outcome measures

PrimaryChange From Baseline to Month 36 in Average Retinal Nerve Fiber Layer Thickness (RNFLT)

The primary endpoint was the change, i.e. the absolute difference, in average RNFL thickness from baseline to month 36 (or last values in case of missing data) in the Full Analysis Set (FAS). Average RNFL thickness was the average of valid measurements of the right and left eye and assessed by optical coherence tomography (OCT).

Time frame:
Baseline, month 36
Reported as:
Mean · micrometer
Change From Baseline to Month 36 in Average Retinal Nerve Fiber Layer Thickness (RNFLT)
micrometerFingolimod - Longitudinal Assessment
Change From Baseline to Month 36 in Average Retinal Nerve Fiber Layer Thickness (RNFLT)-1.5 ± 2.7
SecondaryChange From Baseline to Month 12 and 24 in Average Retinal Nerve Fiber Layer Thickness (RNFLT)

Change from baseline in average RNFL thickness to months 12 and 24 (or last values in case of missing data) in the Full Analysis Set (FAS). Average RNFL thickness was the average of valid measurements of the right and left eye and assessed by optical coherence tomography (OCT).

Time frame:
Baseline, month 12, month 24
Reported as:
Mean · micrometer
Change From Baseline to Month 12 and 24 in Average Retinal Nerve Fiber Layer Thickness (RNFLT)
micrometerFingolimod - Longitudinal Assessment
Change from baseline to month 12-0.8 ± 2.4
Change from baseline to month 24-1.1 ± 2.4
SecondaryChange From Baseline to Month 12, 24 and 36 in Average Quadrant Retinal Nerve Fiber Layer Thickness (RNFLT)

Change from baseline in average quadrant RNFL thickness to months 12, 24 and 36 (or last values in case of missing data) in the Full Analysis Set (FAS). Average quadrant RNFL thickness was the average of valid measurements of the right and left eye and assessed by optical coherence tomography (OCT). Quadrant RNFL thickness were: Nasal-inferior; nasal-superior; temporal-inferior; temporal-superior.

Time frame:
Baseline, month 12, month 24, month 36
Reported as:
Mean · micrometer
Change From Baseline to Month 12, 24 and 36 in Average Quadrant Retinal Nerve Fiber Layer Thickness (RNFLT)
micrometerFingolimod - Longitudinal Assessment
Nasal-superior RNFL thickness: month 120.5 ± 4.0
Nasal-superior RNFL thickness: month 24-0.4 ± 3.4
Nasal-superior RNFL thickness: month 36-0.7 ± 3.9
Nasal-inferior RNFL thickness: month 12-1.2 ± 4.9
Nasal-inferior RNFL thickness: month 24-1.6 ± 5.1
Nasal-inferior RNFL thickness: month 36-2.1 ± 5.2
Temporal-inferior RNFL thickness: month 12-1.2 ± 2.5
Temporal-inferior RNFL thickness: month 24-1.6 ± 3.1
Temporal-inferior RNFL thickness: month 36-2.3 ± 4.1
Temporal-superior RNFL thickness: month 12-0.5 ± 3.9
Temporal-superior RNFL thickness: month 24-0.4 ± 3.4
Temporal-superior RNFL thickness: month 36-1.1 ± 4.1
SecondaryChange From Baseline to Month 12, 24 and 36 in Total Macular Volume (TMV)

Change from baseline in TMV to months 12, 24 and 36 (or last values in case of missing data) in the Full Analysis Set (FAS).

Time frame:
12, 24 and 36 months
Reported as:
Mean · Cubic millimeter
Change From Baseline to Month 12, 24 and 36 in Total Macular Volume (TMV)
Cubic millimeterFingolimod - Longitudinal Assessment
Change from baseline to month 12-0.03 ± 0.08
Change from baseline to month 24-0.04 ± 0.08
Change from baseline to month 36-0.06 ± 0.10
SecondaryChange From Baseline to Month 12, 24 and 36 in Ganglion Cell Inner Plexiform (GCIP)

Change from baseline in GCIP to months 12, 24 and 36 (or last values in case of missing data) in the Full Analysis Set (FAS). The change in Ganglion cell layer thickness (GCLT) had been defined as secondary endpoint in the protocol, but OCT measured the GCIP instead. This was done because both layers were not clearly separable by OCT. GCIP was calculated as mean of the inner sectors (nasal, superior, temporal, and inferior) and declared as usual parameter instead. This change was introduced prior to data base lock, but the derivation of GCIP was corrected after data base lock.

Time frame:
Baseline, month 12, month 24, month 36
Reported as:
Mean · micrometer
Change From Baseline to Month 12, 24 and 36 in Ganglion Cell Inner Plexiform (GCIP)
micrometerFingolimod - Longitudinal Assessment
Change from baseline to month 12-0.49 ± 2.39
Change from baseline to month 24-0.42 ± 2.74
Change from baseline to month 36-0.46 ± 3.01
SecondaryNumber of Participants With Adverse Events

Number of participants with adverse events and specifically macular edema.

Time frame:
36 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsFingolimod - Longitudinal Assessment
No. of subjects with any AE80
No. of subjects with macular edema0

Adverse events

Collected over Adverse events were collected from first dose of study treatment until end of study treatment up to maximum duration of 36 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fingolimod - Longitudinal Assessment0/87 (0%)11/87 (12.6%)68/87 (78.2%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventFingolimod - Longitudinal Assessment
MULTIPLE SCLEROSIS RELAPSENervous system disorders2/87
AORTIC VALVE INCOMPETENCECardiac disorders1/87
ERYSIPELASInfections and infestations1/87
GASTROENTERITIS VIRALInfections and infestations1/87
OPHTHALMIC HERPES ZOSTERInfections and infestations1/87
WOUND INFECTIONInfections and infestations1/87
LOWER LIMB FRACTUREInjury, poisoning and procedural complications1/87
RADIUS FRACTUREInjury, poisoning and procedural complications1/87
SUTURE RELATED COMPLICATIONInjury, poisoning and procedural complications1/87
INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders1/87
Most frequent other events
Showing 10 of 19
Most frequent other events
EventFingolimod - Longitudinal Assessment
NASOPHARYNGITISInfections and infestations41/87
MULTIPLE SCLEROSIS RELAPSENervous system disorders21/87
HYPERTENSIONVascular disorders12/87
HEADACHENervous system disorders10/87
LYMPHOPENIABlood and lymphatic system disorders9/87
VITAMIN D DEFICIENCYMetabolism and nutrition disorders8/87
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations7/87
URINARY TRACT INFECTIONInfections and infestations7/87
BACK PAINMusculoskeletal and connective tissue disorders7/87
DIARRHOEAGastrointestinal disorders6/87

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Fingolimod - Longitudinal Assessment
Mean35.9 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Fingolimod - Longitudinal Assessment
Female55
Male32
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Fingolimod - Longitudinal Assessment
Caucasian84
Other3
08

Study locations

10 sites
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Bonn, 53105, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Duesseldorf, 40225, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Rostock, 18057, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Zuerich, 8091, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2012 to primary completion in Feb 2019, 77 months.

Results were first posted in Mar 2020, 1 year after primary completion.

Of 36 industry-sponsored phase 4 interventional studies under Multiple Sclerosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's 77 months is above that.

Counting every sponsor, half of 69 studies reached it within 34 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2012
First posted
Oct 12, 2012
StartActual
Aug 20, 2012
Primary completionActual
Feb 18, 2019
CompletionActual
Feb 18, 2019
Results first posted
Mar 2, 2020
Last update
Mar 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01705236
Responsible party
Sponsor
First posted
Oct 12, 2012
Start date
Aug 20, 2012
Primary completion
Feb 18, 2019
Completion
Feb 18, 2019
Results posted
Mar 2, 2020
Last update
Mar 2, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion